Eva Godina | Medicine | Best Researcher Award

Posted on by AI Data Scientist

Ms. Eva Godina | Medicine | Best Researcher Award

Medical Student at Maastricht University, Netherlands

Eva Godina is a highly accomplished and internationally active medical student and researcher with a distinctive academic and clinical profile. Currently pursuing a Master of Medicine at Maastricht University in the Netherlands, she combines exceptional academic performance with a strong commitment to advancing research and clinical practices, particularly in oncology and reconstructive surgery. Known for her top-tier achievements, including graduating Cum Laude and receiving the prestigious Dies Natalis Bachelor Award, Eva has consistently demonstrated excellence in both education and research. Her interests span experimental oncology, plastic surgery, and decision support systems for cancer treatment.

Eva’s extensive hands-on experience through clinical electives and observerships at globally renowned institutions such as Harvard Medical School, Stanford, and MD Anderson Cancer Center reflects her dedication to developing her expertise across disciplines and borders. She has co-authored multiple peer-reviewed journal articles, presented at prestigious conferences, and is actively contributing to ongoing clinical and experimental studies. Beyond academics, she is also engaged in mentoring and leadership roles within international organizations, promoting medical education and disease prevention. With a robust foundation in science, communication, and compassion, Eva is poised to become a transformative force in medicine and healthcare innovation.

Profile

ORCID

Education

Eva Godina’s academic journey reflects an outstanding commitment to excellence and a global outlook. She began her medical education at the University of Ljubljana in Slovenia (2018–2019) with an impressive GPA of 8.9 before transferring to Maastricht University’s Faculty of Health, Medicine, and Life Sciences in the Netherlands. There, she completed a Bachelor of Science in Medicine (2019–2022) through the International Track in Medicine, graduating Cum Laude and at the top of her class. Her academic excellence was recognized with the Dies Natalis Bachelor Award, given for outstanding academic results and contributions through her Honours project.

Eva is currently enrolled in the Master of Medicine program at Maastricht University (2023–present), with her graduation expected in August 2025. Prior to university, she attended II. Gymnasium Maribor, Slovenia, graduating in the top 2% internationally with a near-perfect score (44/45). These formative academic experiences laid a strong foundation for her scientific curiosity and global medical perspective. Throughout her education, she has consistently shown the ability to combine rigorous academic pursuits with practical clinical engagement, leadership in extracurricular activities, and meaningful contributions to medical research and community initiatives.

Professional Experience

Eva Godina’s professional medical experience is both rich and international. She has completed high-level clinical internships and observerships in various prestigious institutions, gaining hands-on exposure to plastic and reconstructive surgery, paediatric urology, and oncology. Her recent placements include Harvard Medical School at Massachusetts General Hospital under Dr. Eberlin and Dr. van Mulken (2025–present), as well as Stanford University with Prof. Momeni (2024). She also worked in clinical electives at MUMC+ (Netherlands) and Fundació Puigvert (Spain), specializing in plastic surgery and urology, respectively.

Parallel to her clinical roles, Eva has engaged in diverse research projects. At MD Anderson Cancer Center, she contributed to experimental oncology projects focusing on novel agents for metaplastic breast cancer. At Zuyderland Hospital, she researched Enhanced Recovery After Surgery (ERAS) protocols in colorectal cancer, while at MUMC+, she studied hand-foot syndrome in chemotherapy patients. She also participated in decision-support research for prostate cancer during her Honours program.

In addition to clinical and research work, Eva has contributed to education and communication, serving as a medical illustrator, editor for peer-reviewed journals, and a mentor. These experiences collectively position her as a multi-talented future physician-scientist with a robust international profile.

Research Interest

Eva Godina’s research interests are focused on oncology, particularly breast cancer, reconstructive surgery, and clinical decision-making tools in cancer therapy. Her commitment to translational research that bridges the gap between clinical care and laboratory science is evident in her extensive work with leading cancer institutions and participation in cutting-edge studies. Her projects span experimental and clinical oncology, with a particular interest in metaplastic breast cancer and the use of novel AKT inhibitors, explored during her time at MD Anderson Cancer Center.

Eva also investigates patient-centric outcomes and complications in cancer treatments, such as alpelisib-induced hyperglycemia and hand-foot syndrome, reflecting her interest in precision medicine and improving therapeutic efficacy. Her earlier work involved decision support systems for prostate cancer treatment, demonstrating a strong affinity for digital health tools and AI applications in oncology. These diverse research interests are supported by her participation in research courses by ASCO and AIOM and presentations at leading international conferences such as ASCO and ESMO.

Driven by a desire to enhance clinical protocols and improve patient outcomes, Eva’s research trajectory demonstrates a commitment to innovation, collaborative science, and real-world impact. She envisions a career where she can integrate clinical practice with academic research to advance personalized and evidence-based care.

Research Skills

Eva Godina possesses a broad and well-rounded research skill set, cultivated through academic training, clinical exposure, and active participation in international research collaborations. Her core competencies include clinical research design, data collection and analysis, patient outcome assessments, and manuscript preparation. She is adept at both quantitative and qualitative methodologies, evidenced by her contributions to mixed-method studies, such as the 23-hour enhanced recovery program research published in BMC Health Services Research.

Eva has hands-on experience with oncology trials and observational studies, particularly in breast cancer therapeutics and complications. Her research includes real-world outcome analysis, systematic therapy evaluation, and adverse event correlation—skills she utilized in multiple conference presentations and journal submissions. Furthermore, she is skilled in case study preparation, notably on targeted therapies for metaplastic breast cancer.

Her editorial experience as a peer-reviewed journal editor and illustrator for anatomical diagrams at Maastricht University also highlights her ability to translate complex scientific content into accessible formats. She has also completed specialized clinical research training courses by ASCO and AIOM, further strengthening her theoretical and practical research acumen. These capabilities equip her to navigate interdisciplinary medical research, contributing to both scientific literature and clinical innovation.

Awards and Honors

Eva Godina’s academic and professional journey is decorated with prestigious awards and scholarships recognizing her excellence, talent, and contributions to the field of medicine. Most notably, she received the Dies Natalis Bachelor Award in 2022 for her exceptional study results and Honours research project at Maastricht University, a distinction reserved for top-performing students.

She was also a recipient of the Zois Scholarship, awarded to gifted high school and university students in Slovenia, which she held during both her high school years (2013–2018) and university studies (2023–present). This long-term recognition underscores her consistent academic prowess.

In support of her international education, Eva received the Ad Futura Study Abroad Scholarship from 2020 to 2022, which helped fund her studies in the Netherlands. In 2024, she was awarded a Travel Grant from ASCO to attend a clinical research course, reinforcing her global engagement in cancer research and education.

These awards reflect not only her outstanding academic and research performance but also her proactive involvement in international academic circles. They serve as a testament to her commitment to excellence, innovation, and continuous learning in medical science.

Publications

Eva Godina has an impressive record of scholarly contributions, including peer-reviewed publications, manuscripts under review, and several international conference abstracts and posters. Among her published work, she co-authored a study in BMC Health Services Research (2024) on the implementation of a 23-hour accelerated recovery program, showcasing her interest in health services optimization. She also contributed to an important Annals of Oncology (2020) paper on long-term outcomes with neoadjuvant systemic therapy in breast cancer.

Her work continues with manuscripts currently under review, including a study on prehabilitation programs for colorectal cancer patients submitted to Nutrients, and a case report on a novel AKT inhibitor for metaplastic breast cancer, targeting submission to BJC Reports.

Eva has also presented at internationally renowned conferences. Notably, she was the first author on an abstract presented at ASCO 2023 examining predictors of alpelisib-induced hyperglycemia. She has also presented at the Slovenian Senologic Society’s Oncology Weekend and ESMO 2020.

These publications and presentations affirm her as a rising academic voice in oncology, patient-centered care, and translational medical research, with a strong commitment to contributing to the broader medical and scientific community.

Conclusion

Eva Godina stands out as a promising and multi-talented future physician-scientist whose journey is marked by academic distinction, international clinical experience, and impactful research. Her academic path has been characterized by excellence from the outset, with top-of-the-class honors and awards that recognize both her intellectual capacity and her proactive contributions to science and healthcare.

Through a blend of rigorous education, diverse internships, and in-depth research, Eva has cultivated a multifaceted skill set that positions her at the forefront of modern medicine. Her research in oncology and surgery, particularly with prestigious institutions like MD Anderson and Harvard, is a testament to her global engagement and dedication to advancing medical knowledge.

Moreover, Eva’s involvement in mentoring, leadership, and volunteer initiatives reflects her well-rounded character and deep commitment to service. Her future trajectory promises significant contributions to medical science, especially in areas requiring precision, compassion, and innovation. As she continues her Master’s studies and clinical training, Eva is set to emerge as a leader in both the scientific and clinical communities, exemplifying excellence in every facet of her profession.

Irene Ruengkhachorn | Medicine | Women Researcher Award

Posted on by AI Data Scientist

Assoc. Prof. Dr. Irene Ruengkhachorn | Medicine | Women Researcher Award

Associate Professor at Faculty of Meidicine Siriraj Hospital, Mahidol university, Thailand

Dr. Irene Ruengkhachorn is a dedicated academic and clinical specialist in gynecologic oncology, currently serving as an Associate Professor at the Faculty of Medicine Siriraj Hospital, Mahidol University. With nearly two decades of medical and teaching experience, she has significantly contributed to the field through research, clinical practice, and education. Dr. Ruengkhachorn’s expertise spans minimally invasive surgery, integrative oncology, and advanced gynecologic cancer treatment protocols. Her scholarly activities have earned her recognition within the national and international medical community, where she continues to drive progress in women’s cancer care.

Profile

Orcid

Education

Dr. Ruengkhachorn has pursued a thorough and distinguished academic journey. She earned her Doctor of Medicine degree from the Faculty of Medicine Siriraj Hospital, Mahidol University, in 2000. She continued her postgraduate training at the same institution, completing graduate diplomas in Basic and Clinical Sciences in 2004 and 2005, respectively. She further specialized by earning a Thai Board certification in Obstetrics and Gynecology in 2006, and in Gynecologic Oncology from Chiangmai University in 2008. Her interest in surgical techniques led her to complete certifications in gynecologic laparoscopic surgery in 2012 and undergo visiting clinical training in minimally invasive surgery at Mayo Clinic, USA, the same year. In 2017, she added a Certificate of Advanced Medical Epidemiology from Thammasat University, equipping her with robust research design and analysis capabilities.

Experience

Dr. Ruengkhachorn began her academic career as an Instructor in 2009 at Siriraj Hospital, advancing to Assistant Professor in 2013 and later to Associate Professor in 2016. Over the years, she has played a central role in mentoring medical students and residents, particularly in gynecologic oncology rotations. Prior to her tenure at Siriraj Hospital, she also served as a tutor in the Gynecologic Oncology Department at Chiangmai University. Her long-standing service in one of Thailand’s leading tertiary care centers has enabled her to influence treatment protocols and participate in numerous multi-disciplinary teams that shape national cancer care standards.

Research Interest

Dr. Ruengkhachorn’s research interests are grounded in the clinical challenges of gynecologic oncology. She focuses on cervical and ovarian cancer management, outcomes of surgical interventions, and predictive biomarkers. Her work extends into evaluating oncologic outcomes, the role of pathology in treatment planning, and recently, integrating artificial intelligence and precision medicine approaches. She has also explored minimally invasive surgical techniques, HPV-related cytological abnormalities, and the role of traditional medicine in cancer care. Her aim is to translate clinical findings into practice guidelines that improve survival and quality of life for women affected by reproductive cancers.

Award

Her research has received multiple accolades that highlight both scientific rigor and relevance. In 2008, she won the GSK Research Award for her work on predicting the need for adjuvant radiotherapy in early-stage cervical cancer. The R2R Research Award followed in 2014, recognizing her investigation into atypical glandular cells in cytology. In 2017, she earned the “Research of the Month” title at Siriraj Hospital for her landmark study on outcomes of advanced cervical carcinoma treated with chemotherapy at a tertiary referral center. These honors underscore her contributions to evidence-based gynecologic oncology in high-incidence settings.

Publication

Dr. Ruengkhachorn has published extensively in peer-reviewed journals. Seven representative publications include:

  1. Ruengkhachorn I et al., “Oncologic outcomes of stage IVB or persistent or recurrent cervical carcinoma patients treated with chemotherapy,” Int J Gynecol Cancer, 2016, cited 49 times.

  2. Ittiamornlert P, Ruengkhachorn I, “Neutrophil-lymphocyte ratio as a predictor of oncologic outcomes,” BMC Cancer, 2019, cited 61 times.

  3. Ruengkhachorn I et al., “Undiagnosed uterine sarcomas identified during surgery for presumed leiomyoma,” Int J Gynecol Cancer, 2017, cited 34 times.

  4. Ruengkhachorn I et al., “Comparison of oncologic outcomes of unanticipated cervical carcinoma,” Gynecol Oncol, 2019, cited 57 times.

  5. Phianpiset R, Ruengkhachorn I et al., “ASCCP risk-based colposcopy recommendations in Thai women,” Obstet Gynecol, 2020, cited 66 times.

  6. Ruengkhachorn I et al., “Predicting factors associated with resistance to Methotrexate in GTN,” Asian Pac J Clin Oncol, 2022, cited 23 times.

  7. Ruengkhachorn I et al., “High-risk HPV genotyping in atypical squamous cells,” Scientific Reports, 2023, cited 15 times.
    These publications reflect her diverse yet focused contributions in clinical oncology and diagnostic advancement.

Conclusion

Dr. Irene Ruengkhachorn has emerged as a leader in gynecologic oncology in Thailand through her relentless pursuit of clinical excellence, academic advancement, and translational research. Her academic path, enriched by international exposure and cross-disciplinary integration, positions her at the forefront of modern cancer care. As she continues to mentor young physicians, publish impactful research, and lead clinical innovation, Dr. Ruengkhachorn exemplifies the synergy of research and compassionate care in advancing women’s health. Her ongoing engagement with global research communities ensures her contributions remain both relevant and far-reaching in the evolving field of gynecologic oncology.

Ahmad Khaleel Alomari | Drug Delivery System, Nano Technology | Best Researcher Award

Posted on by AI Data Scientist

Assist. Prof. Dr. Ahmad Khaleel Alomari | Drug Delivery System, Nano Technology | Best Researcher Award

Assistant Professor at Prince Sattam bin Abdualaziz University, Saudi Arabia

Dr. Ahmad Khaleel AlOmari is a distinguished academic and Assistant Professor at Prince Sattam bin Abdulaziz University, recognized for his dynamic contributions to information systems, data analytics, and biomedical technologies. With a strong foundation in intelligent systems and computational analytics, his work integrates advanced technologies such as nanotechnology and knowledge management to develop impactful and interdisciplinary solutions. His scholarly endeavors have earned him a prominent reputation in both academic and professional circles, particularly for his innovative research in semantic technologies, health informatics, and machine learning applications.

Profile

ORCID

Education

Dr. AlOmari’s educational journey has been defined by a commitment to excellence and interdisciplinary depth. With formal training in information systems, biomedical engineering, and computational sciences, he has cultivated an academic profile that supports a cross-functional understanding of technology and its practical implications. His education has empowered him to bridge the gap between theoretical innovation and real-world application, particularly in the domains of intelligent medical systems, nanomaterials, and data-driven decision-making processes.

Experience

Since 2008, Dr. AlOmari has served in various academic roles, notably at King Saud University before joining Prince Sattam bin Abdulaziz University. His career has been marked by involvement in teaching undergraduate and postgraduate students, curriculum development, and supervising research theses. He has also led and collaborated on numerous funded research projects, building strong connections with both academic institutions and industry stakeholders. His work extends to consultancy roles, enabling him to contribute directly to government and private sector advancements through the integration of AI and data systems in applied settings.

Research Interest

Dr. AlOmari’s research interests lie at the intersection of data analytics, intelligent systems, and biomedical engineering. His work focuses on the development of predictive models and diagnostic tools using machine learning, data mining, and semantic technologies. His contributions to nanotechnology-based drug delivery systems and biosensing mechanisms reflect his commitment to leveraging computational tools for improving healthcare outcomes. Additionally, his research explores strategic data use, information quality, and digital transformation in public and private sectors, illustrating his diverse and interdisciplinary research focus.

Award

Dr. Ahmad Khaleel AlOmari is a nominee for the AI Data Scientist Awards under the “Best Researcher Award” category. This nomination acknowledges his extensive scholarly contributions, sustained research excellence, and global collaborations that align with the prestigious objectives of the award. His interdisciplinary innovations and long-standing commitment to research leadership exemplify the qualities of an outstanding scientist in the modern digital landscape.

Publication

Dr. AlOmari has authored numerous impactful studies, with his recent work gaining attention in high-quality peer-reviewed journals. Seven selected publications include:

  1. “DFT Insights into Assembling [8]Mcpp with [14]Pyridine Nanobelts for Amino Acid Sensing,” Journal of Molecular Graphics and Modelling, 2025, has been cited in theoretical chemistry research for its novel nanobelt configuration.

  2. “Rapid and Efficient Detection of Acetone Using C20-Based Nanostructures,” Diamond and Related Materials, 2025, supports non-invasive diabetes diagnostics and has influenced biosensor innovation studies.

  3. “Nanozymes for Multi-mode Biosensing in Food Safety,” Journal of Environmental Chemical Engineering, 2025, is frequently cited in environmental monitoring literature.

  4. “AI-Driven Assessment for Mechanical Performance of UVC-Treated Date Palm Epoxy Composites,” Polymers, 2025, merges AI with sustainable materials and is referenced in materials engineering works.

  5. “Depressive Symptoms Among Elderly Cancer Patients,” Asian Pacific Journal of Cancer Prevention, 2024, is noted in mental health and oncology-related discussions.

  6. “Effectiveness of an Educational Program on Pacemaker Patients,” International Journal of Africa Nursing Sciences, 2024, is recognized in patient rehabilitation and care management articles.

  7. “Muscle Relaxation to Mitigate Anxiety in COVID-19 Survivors,” International Journal of Africa Nursing Sciences, 2024, has contributed to post-pandemic mental health literature.

Conclusion

In conclusion, Dr. Ahmad Khaleel AlOmari exemplifies the qualities of an innovative and impactful researcher. His interdisciplinary expertise, spanning computational science, health informatics, and material engineering, allows him to tackle real-world problems through cutting-edge technologies. Through sustained academic engagement, international collaboration, and high-impact publications, Dr. AlOmari has significantly contributed to scientific progress and societal well-being. His ongoing efforts continue to inspire and shape the future of AI-driven research and development, marking him as a deserving candidate for recognition under the AI Data Scientist Awards.